CDDO-2P-Imidazolide

Cas No.:	1883650-96-1
Chemical Name:	CDDO-2P-Imidazolide
Synonyms:	CDDO-2-P-Im;CDDO-2P-Im;CDDO-2P-Imidazolide
SMILES:	O=C1C([H])=C2[C@@]3(C([H])=C(C#N)C(C(C([H])([H])[H])(C([H])([H])[H])C3([H])C([H])([H])C([H])([H])[C@]2(C([H])([H])[H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@]3(C(N4C([H])=NC(C5=C([H])C([H])=C([H])C([H])=N5)=C4[H])=O)C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[C@@]3([H])[C@@]21[H])=O)C([H])([H])[H]
Formula:	C39H46N4O3
M.Wt:	618.8075
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	CDDO-2P-Im is an analogue of CDDO-Imidazolide with chemopreventive effect. CDDO-2P-Im can reduce the size and the severity of the lung tumors in mouse lung cancer model[1].
In Vivo:	CDDO-2P-Im is more stable than CDDO-Im in pharmacokinetic studies[1]. CDDO-2P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1]. CDDO-2P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1]. Animal Model: Seven week-old female A/J mice[1] Dosage: 50 mg/kg, 200 mg/kg Administration: Diet; for 16 weeks Result: Decreased the number, the size and the severity of tumors.
In Vitro:	CDDO-2P-Im (100 nM; 4 days) induces differentiation of U937 cells at 100 nM[1]. CDDO-2P-Im suppresses NO production in RAW264.7 cells with an IC50 of 5.8 nM[1]. Apoptosis Analysis[1] Cell Line: U937 cells Concentration: 30 nM, 100 nM Incubation Time: 4 days Result: Induced differentiation of U937 cells at 100 nM.
References:	[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47. [2]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.